Myelodysplastic syndrome after breast cancer. The challenge of late complications in long-term survivors

The therapy related myeloid neoplasms (t-MN) include the cases of therapy related myelodysplastic syndrome (t-MDS) and therapy related acute myeloid leukemia (t-AML) that occurs as a late complication of chemotherapy and/or radiotherapy administered to treat a previous neoplastic disease [1]. The alkylating agents and the topoisomerase II inhibitors are commonly implicated in the etiology of the disease, with a shorter latency period, 1 –5 years, for the topoisomerase II inhibitors. Most of patients with t-AML/t-MDS show an abnormal karyotype.

Source: Leukemia Research - August 22, 2016 Category: Hematology Authors: Patricia Font Tags: Editorial Source Type: research